Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $199.1B | - | $5.7B | $3.2B | 12.9% | 12.6% | -5.3% |
| 2024 | $176.8B | - | $6.0B | $4.6B | 14.5% | 3.2% | -0.1% |
| 2023 | $171.3B | - | $6.0B | $6.8B | 15.2% | 9.4% | 1.6% |
| 2022 | $156.6B | - | $5.9B | $7.2B | 16.3% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 156,595 | 171,340 | 176,810 | 199,125 |
| Operating Revenue | - | 156,595 | 171,340 | 176,810 | 199,125 |
| Selling General And Administration | 15,914 | 17,686 | - | - | - |
| Total Expenses | - | 148,995 | 163,625 | 168,906 | 192,415 |
| EBIT | - | 8,451 | 8,745 | 9,089 | 8,112 |
| Interest Expense | - | 851 | 1,030 | 1,185 | 1,402 |
| Net Interest Income | - | -851 | -1,030 | -1,185 | -1,402 |
| Other Income Expense | - | 14,978 | 19,452 | 22,630 | 24,470 |
| Interest Expense Non Operating | - | 851 | 1,030 | 1,185 | 1,402 |
| Net Non Operating Interest Income Expense | - | -851 | -1,030 | -1,185 | -1,402 |
| Pretax Income | - | 7,600 | 7,715 | 7,904 | 6,710 |
| Tax Provision | - | 1,712 | 1,724 | 1,933 | 1,049 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 49.24 | 0 |
| Net Income Continuous Operations | - | 5,888 | 5,991 | 5,971 | 5,661 |
| Net Income From Continuing And Discontinued Operation | - | 5,894 | 5,987 | 5,980 | 5,662 |
| Net Income From Continuing Operation Net Minority Interest | - | 5,894 | 5,987 | 5,980 | 5,662 |
| Net Income | - | 5,894 | 5,987 | 5,980 | 5,662 |
| Net Income Common Stockholders | - | 5,894 | 5,987 | 5,980 | 5,662 |
| Net Income Including Noncontrolling Interests | - | 5,888 | 5,991 | 5,971 | 5,661 |
| Normalized Income | - | 5,894 | 5,987 | 5,828.24 | 5,662 |
| Diluted NI Availto Com Stockholders | - | 5,894 | 5,987 | 5,980 | 5,662 |
| Basic Average Shares | - | 237.96 | 233.07 | 227.48 | 220.72 |
| Diluted Average Shares | - | 242.80 | 237.40 | 232.90 | 224.60 |
| Reconciled Depreciation | - | 1,675 | 1,745 | 1,393 | 1,546 |
| Total Unusual Items | - | 0 | 0 | 201 | 0 |
| Total Unusual Items Excluding Goodwill | - | 0 | 0 | 201 | 0 |
| Minority Interests | - | 6 | -4 | 9 | 1 |
| Special Income Charges | - | 0 | 0 | 201 | 0 |
| Other Special Charges | 21 | - | - | -201 | - |
| Depreciation And Amortization In Income Statement | - | 767 | 885 | 580 | 628 |
| Other Operating Expenses | - | 30,735 | 37,380 | 39,775 | 42,162 |
| Amortization | - | 767 | 885 | 580 | 628 |
| Loss Adjustment Expense | - | 116,642 | 124,330 | 127,567 | 148,223 |
| Net Policyholder Benefits And Claims | - | 116,642 | 124,330 | 127,567 | 148,223 |
| Policyholder Benefits Gross | - | 116,694 | 124,393 | 127,623 | 148,295 |
| Policyholder Benefits Ceded | - | 52 | 63 | 56 | 72 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Elevance Health, Inc.this co. | ELV | $88.9B | 15.70↓ discount | 2.03 | 12.9% | - |
| Stryker Corporation | SYK | $115.5B | 35.57 | 5.15 | 14.5% | 20.16 |
| Vertex Pharmaceuticals Incorporated | VRTX | $112.1B | 28.36 | 6.01 | 21.2% | 22.41 |
| Medtronic plc | MDT | $105.2B | 22.56 | 2.19 | 9.7% | 14.26 |
| McKesson Corporation | MCK | $91.0B |
| - |
| - |
| - |
| - |
| - |
| 19.11 |
| -41.89 |
| -219.2% |
| 13.32 |
| HCA Healthcare, Inc. | HCA | $80.3B | 11.83 | -13.32 | -112.6% | 8.20 |
| The Cigna Group | CI | $74.2B | 12.46 | 1.78 | 14.3% | 10.24 |
| Boston Scientific Corporation | BSX | $72.6B | 25.05 | 3.00 | 12.0% | 16.09 |
| Regeneron Pharmaceuticals, Inc. | REGN | $65.9B | 14.63 | 2.11 | 14.4% | 11.26 |
| Peer Median | - | 20.84 | 2.15 | 13.1% | 13.79 | |
Historically, Apr has averaged the highest return (+6.3%); Jul the lowest (-4.4%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -1.4%Neutral MonthJan 2026: -1.37% | -7.4%Negative MonthFeb 2026: -7.44% | -8.5%Negative MonthMar 2026: -8.52% | +28.6%Positive MonthApr 2026: +28.58% | +4.5%Positive MonthMay 2026: +4.46% | -1.6%Neutral MonthJun 2026: -1.64% | -2.8%Negative MonthJul 2026: -2.82% | +6.0%*Positive MonthAug 2026: +6.02% | — | — | — | — |
| 2025 | +7.3%Positive MonthJan 2025: +7.26% | +0.3%Neutral MonthFeb 2025: +0.30% | +9.6%Positive MonthMar 2025: +9.59% | -3.3%Negative MonthApr 2025: -3.31% | -8.7%Negative MonthMay 2025: -8.74% | +1.3%Neutral MonthJun 2025: +1.33% | -27.2%Negative MonthJul 2025: -27.22% | +12.6%Positive MonthAug 2025: +12.57% | +1.4%Neutral MonthSep 2025: +1.40% | -1.8%Neutral MonthOct 2025: -1.83% | +6.6%Positive MonthNov 2025: +6.64% | +3.6%Positive MonthDec 2025: +3.63% |
| 2024 | +4.6%Positive MonthJan 2024: +4.64% | +1.6%Neutral MonthFeb 2024: +1.58% | +3.4%Positive MonthMar 2024: +3.45% | +1.9%Neutral MonthApr 2024: +1.94% | +1.9%Neutral MonthMay 2024: +1.87% | +0.6%Neutral MonthJun 2024: +0.63% | -1.8%Neutral MonthJul 2024: -1.81% | +4.7%Positive MonthAug 2024: +4.67% | -6.6%Negative MonthSep 2024: -6.62% | -22.0%Negative MonthOct 2024: -21.97% | +0.3%Neutral MonthNov 2024: +0.30% | -9.4%Negative MonthDec 2024: -9.35% |
| 2023 | -2.5%Negative MonthJan 2023: -2.53% | -6.1%Negative MonthFeb 2023: -6.06% | -2.1%Negative MonthMar 2023: -2.10% | +1.9%Neutral MonthApr 2023: +1.92% | -4.4%Negative MonthMay 2023: -4.44% | -0.8%Neutral MonthJun 2023: -0.79% | +6.2%Positive MonthJul 2023: +6.15% | -6.3%Negative MonthAug 2023: -6.28% | -1.5%Neutral MonthSep 2023: -1.49% | +3.4%Positive MonthOct 2023: +3.37% | +6.5%Positive MonthNov 2023: +6.53% | -1.7%Neutral MonthDec 2023: -1.65% |
| 2022 | -4.9%Negative MonthJan 2022: -4.86% | +2.5%Positive MonthFeb 2022: +2.46% | +8.7%Positive MonthMar 2022: +8.71% | +2.2%Positive MonthApr 2022: +2.18% | +1.5%Neutral MonthMay 2022: +1.53% | -5.3%Negative MonthJun 2022: -5.30% | -1.1%Neutral MonthJul 2022: -1.14% | +1.7%Neutral MonthAug 2022: +1.68% | -6.4%Negative MonthSep 2022: -6.36% | +20.4%Positive MonthOct 2022: +20.37% | -2.5%Negative MonthNov 2022: -2.53% | -3.7%Negative MonthDec 2022: -3.74% |
| 2021 | — | — | — | — | +5.0%Positive MonthMay 2021: +4.96% | -4.1%Negative MonthJun 2021: -4.12% | +0.6%Neutral MonthJul 2021: +0.58% | -2.3%Negative MonthAug 2021: -2.31% | -0.6%Neutral MonthSep 2021: -0.62% | +16.7%Positive MonthOct 2021: +16.72% | -6.6%Negative MonthNov 2021: -6.64% | +14.1%Positive MonthDec 2021: +14.11% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
